Short Interest in Co-Diagnostics Inc (NASDAQ:CODX) Grows By 6.3%

Co-Diagnostics Inc (NASDAQ:CODX) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 755,100 shares, an increase of 6.3% from the May 15th total of 710,400 shares. Based on an average trading volume of 257,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 7.3% of the company’s shares are short sold.

NASDAQ CODX traded down $0.15 on Friday, reaching $0.94. The company had a trading volume of 1,624,444 shares, compared to its average volume of 1,633,132. The company has a 50 day moving average of $0.82. Co-Diagnostics has a 52 week low of $0.69 and a 52 week high of $4.15.

Co-Diagnostics (NASDAQ:CODX) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). Co-Diagnostics had a negative net margin of 19,057.66% and a negative return on equity of 430.95%.

A number of equities research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating on shares of ACASTI PHARM-TS in a research report on Wednesday, June 26th. Maxim Group set a $25.00 target price on Agilysys and gave the stock a “buy” rating in a research report on Friday, May 17th. Finally, Zacks Investment Research upgraded Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a report on Monday, July 8th.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc was founded in 2013 and is headquartered in Salt Lake City, Utah.

See Also: Earnings Per Share (EPS) Explained

Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with's FREE daily email newsletter.